Last reviewed · How we verify
Tarceva (erlotinib HCl)
Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase.
Tarceva (erlotinib HCl) works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase. Used for Non-small cell lung cancer, pancreatic cancer, and other types of cancer, Locally advanced or metastatic non-small cell lung cancer.
At a glance
| Generic name | Tarceva (erlotinib HCl) |
|---|---|
| Also known as | OSI-774 |
| Sponsor | Genentech, Inc. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents the activation of downstream signaling pathways that promote cell proliferation and survival, ultimately leading to the death of cancer cells. Erlotinib has been shown to be effective in treating non-small cell lung cancer, pancreatic cancer, and other types of cancer. The exact mechanism of action is complex and involves multiple molecular pathways.
Approved indications
- Non-small cell lung cancer, pancreatic cancer, and other types of cancer
- Locally advanced or metastatic non-small cell lung cancer
Common side effects
- Rash
- Diarrhea
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (PHASE1)
- Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (PHASE1)
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer (PHASE2)
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (PHASE1)
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (PHASE3)
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tarceva (erlotinib HCl) CI brief — competitive landscape report
- Tarceva (erlotinib HCl) updates RSS · CI watch RSS
- Genentech, Inc. portfolio CI